CSIMarket


Olema Pharmaceuticals inc   (OLMA)
Other Ticker:  
 


 

Olema Pharmaceuticals inc

OLMA's Financial Statements and Analysis



Olema Pharmaceuticals inc narrowed third quarter of 2023 net loss per share of $-0.48 compare to net loss per share of $-0.57 recorded in the same quarter a year ago and improved compare to net loss per share of $-0.49 realized in previous quarter.


third quarter of 2023
Earnings Per Share Revenues
$ -0.48 $  0 Mill
$+0.09     Unch.    



Olema Pharmaceuticals Inc 's Revenue fell by 0 % in third quarter of 2023 (Sep 30 2023) year on year, to $0 million and declined by sequentially.


Olema Pharmaceuticals Inc is

More on OLMA's Income Statement



Olema Pharmaceuticals Inc in the third quarter of 2023 recorded net loss of $-21.502 million, an improvement compare to net loss of $-22.720 million in III. Quarter a year ago.

Sequentially net loss advanced

More on OLMA's Growth

Olema Pharmaceuticals Inc Inventories
OLMA's Cash flow In the third quarter of 2023 company's net cash flow was $82 million


Olema Pharmaceuticals inc does not pay out common stock dividend.

In trailing twelve-month period Olema Pharmaceuticals inc payed $ -1.89 cash per share, on a free-cash flow basis .

Book value grew by 54.16 % sequentially to $6.12 per share.
Tangible Book value grew to $ 6.12 per share from $ 3.97.

Company issued 4.26 million shares or 10.45 % in Sep 30 2023.


More on OLMA's Dividends

 Market Capitalization (Millions) 407
 Shares Outstanding (Millions) 45
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -96
 Cash Flow (TTM) (Millions $) 91
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 30




Olema Pharmaceuticals inc does not pay out common stock dividend.

In trailing twelve-month period Olema Pharmaceuticals inc had negative $ -1.89 cash flow per share, on a free-cash flow basis .

Book value grew by 54.16 % sequentially to $6.12 per share.
Tangible Book value grew to $ 6.12 per share from $ 3.97.

Company issued 4.26 million shares or 10.45 % in Sep 30 2023.


More on OLMA's Balance Sheets

 Market Capitalization (Millions) 407
 Shares Outstanding (Millions) 45
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -96
 Cash Flow (TTM) (Millions $) 91
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 30
   


  News about Olema Pharmaceuticals inc Earnings

Major Pharmaceutical Preparations Company Faces Operating Shortfall, But Optimism Grows for Future Success

Financial News Report: Olema Pharmaceuticals Reports Operating Shortfall but Shows Promise in Diminishing Returns
During the earnings season from July to September 30, 2023, numerous companies have released their financial results. Among them are several companies in the Major Pharmaceutical Preparations sector, including OLMA. OLMA recently reported an operating shortfall of $-23.342 million for the same time frame. However, stakeholders are optimistic about the potential of a new business model in the upcoming cycle. Shareholders appear to be less concerned about the current organizational and operational performance of the Major Pharmaceutical Preparations company.
One positive note is that the di...

Olema Pharmaceuticals Inc Faces Steep Decline in Earnings, Threatening Industry Dominance

Bearish Sentiment Surrounds Olema Pharmaceuticals Inc as Earnings Disappoint
During the ongoing earnings season of April to June 30, 2023, numerous companies have released their financial numbers, including several constituents of the Major Pharmaceutical Preparations sector. One such company is Olema Pharmaceuticals Inc, which recently revealed an operating shortfall of $-21.601 million for the most recent fiscal period. This highlights a worrying trend in terms of the company's productivity compared to the financial timeframe ending June 30, 2022.
Operating primarily in the expansion span, Olema Pharmaceuticals Inc's latest report indicates a lackluster performance. The primary takeaway from this r...

Olema Pharmaceuticals' Expense Burden Mounts in Q1 2023, Records Net Loss of $110 Million

As a journalist interpreting Olema Pharmaceuticals Inc's financial results, I must report that the company recorded a net loss of $-110 million during the 12 months ending in the first quarter of 2023. This has resulted in a negative return on investment (ROI) of -52.83%. Unfortunately, this means that within the Healthcare sector, there are 574 other companies with a higher return on investment.
Furthermore, the company's total ranking has deteriorated, dropping from 0 in the fourth quarter of 2022 to 4013. This is not a good sign for investors, and it means that Olema Pharmaceuticals Inc has a long way to go to catch up to it...


Date modified: 2023-11-08T15:48:50+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com